📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Clinical Monitoring Plan (OBX319-301)

Document ID: TMF-003
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH E6(R3)

Clinical Monitoring Plan — OBX319-301

Describes the risk-based monitoring approach for OBX319-301: site qualification, initiation, routine on-site and centralised monitoring, source-data verification strategy, key risk indicators, and close-out, to protect subject safety and data integrity. ICH E6(R3).

1. Purpose and Scope

This Clinical Monitoring Plan (CMP) operationalises the sponsor's oversight of OBX319-301, a Phase 3, randomized, double-blind, placebo-controlled study of OBX-319 in adults with moderate-to-severe active Systemic Lupus Erythematosus (SLE) on background standard-of-care (SoC). It defines the strategy, methods, frequency, roles, and documentation for monitoring across all participating sites, and describes how monitoring activities verify that the rights, safety, and well-being of subjects are protected; that reported data are accurate, complete, and verifiable against source; and that the trial is conducted in compliance with the protocol, ICH E6(R3), applicable regulatory requirements, and sponsor procedures.

OBX-319 is a humanized IgG1 bispecific monoclonal antibody that simultaneously engages CD19 and CD20 to deplete B cells, produced by Chinese hamster ovary (CHO) cell culture and administered subcutaneously. Because the mechanism of action is profound B-lineage depletion, the monitoring design is deliberately weighted toward the identified class risks of B-cell-directed therapy — serious and opportunistic infection and hypogammaglobulinaemia — and toward the modality-specific data domains that reviewers will scrutinise, namely pharmacodynamic (PD) B-cell enumeration, pharmacokinetics (PK) governed by target-mediated drug disposition (TMDD), immunogenicity/anti-drug antibody (ADA) assessment, and injection-related reactions.

This plan is a controlled document within the Trial Master File (TMF) and is read in conjunction with the protocol, the Safety Management Plan (TMF-006), the Data Safety Monitoring Board Charter (TMF-004), the Data Management Plan (TMF-002), the Randomization & IWRS Plan (TMF-012), the Pharmacy Manual (TMF-010), the Laboratory Manual (TMF-011), and the Informed Consent Form (TMF-001). Where any conflict arises between this plan and the protocol, the protocol prevails for subject-level conduct; discrepancies are escalated for resolution and documented.

2. Study Overview and Investigational Product

Design. OBX319-301 is a randomized, double-blind, placebo-controlled, three-arm study with 1:1:1 allocation and a 52-week double-blind treatment period, conducted on background SoC. A total of 480 subjects were randomized: 162 to the High-dose OBX-319 arm, 158 to the Low-dose OBX-319 arm, and 160 to placebo. Enrolment targets subjects with moderate-to-severe active SLE (baseline SLEDAI-2K approximately 11) despite standard therapy. Randomization is managed through the IWRS/IRT and stratified per TMF-012; treatment assignment is concealed from subjects, investigators, site staff, and the blinded monitoring team.

Primary and key secondary endpoints. The primary efficacy endpoint is the SRI-4 response with attainment of low disease activity (SLEDAI-2K ≤ 4) at Week 52; the key secondary endpoint is the change from baseline in SLEDAI-2K. These composite and instrument-derived endpoints depend on faithful, consistently scored source data (SLEDAI-2K, physician global assessment, BILAG organ-domain scoring, and protocol-specified corticosteroid tapering), and are therefore designated critical data for the source-data-review strategy in Section 10.

Investigational product and administration. OBX-319 drug product and its matching placebo are supplied for subcutaneous administration and require refrigerated storage at 2–8 °C, protection from light, and handling that avoids shaking or freezing to preserve the integrity of the antibody and prevent aggregation, consistent with the Pharmacy Manual (TMF-010). Monitors confirm site adherence to cold-chain conditions, temperature-excursion procedures, dose preparation, subcutaneous administration technique, and the post-administration observation period for injection reactions.

Pharmacodynamics, pharmacokinetics, and immunogenicity. The pharmacodynamic hallmark of OBX-319 is near-complete depletion of circulating CD19+ B cells on active treatment (approximately 210 cells/µL at baseline falling to approximately 7 cells/µL), with placebo essentially unchanged; accompanying markers include a fall in anti-dsDNA and normalisation of complement C3/C4 in responders. B-cell enumeration is performed by flow cytometry on time-sensitive whole-blood samples, PK exhibits TMDD driven by the B-cell target sink, and immunogenicity (ADA and, where indicated, neutralising-antibody assessment) is evaluated on a defined schedule. Oversight of the collection, handling, and shipment of these samples is a specific monitoring focus (Section 15).

3. Monitoring Strategy and Risk-Based Quality Management

Monitoring follows the risk-based, quality-by-design framework of ICH E6(R3). Rather than uniform 100% on-site source-data verification, the sponsor applies a proportionate, blended model combining (a) targeted on-site monitoring, (b) centralised/statistical monitoring of accumulating data, and (c) remote review, calibrated to the criticality of each data element and to observed site performance. The intensity and frequency of monitoring are not fixed but adapt to real-time risk signals: sites demonstrating strong quality metrics may receive reduced on-site frequency, while sites triggering key risk indicators (KRIs) or quality-tolerance-limit (QTL) excursions receive intensified, for-cause attention.

The strategy is documented, versioned, and revisited across the trial lifecycle. The Integrated Quality Risk Management (IQRM) assessment underpinning it identifies critical-to-quality (CtQ) factors, the risks to each, and the mitigations — with monitoring being one mitigation among several (others include protocol design, site training, EDC edit checks, and central lab controls). This plan is a living document; material changes to the risk profile or to monitoring intensity are captured through version control and communicated to the monitoring team and, where relevant, to sites.

4. Critical-to-Quality Factors and Risk Assessment

Critical-to-quality factors for OBX319-301, and the associated risks that shape monitoring emphasis, include the following.

• Subject eligibility and safety screening. Correct confirmation of moderate-to-severe active SLE, and the infection-risk screening appropriate to a B-cell-depleting agent — including tuberculosis, hepatitis B (HBV) and hepatitis C (HCV) status, and baseline immunoglobulins — is critical. Errors risk enrolling ineligible or unsafe subjects and are monitored at 100% source verification.
• Serious and opportunistic infection surveillance. As an identified class risk of B-cell depletion, infections (including opportunistic infections, HBV reactivation, and consideration of progressive multifocal leukoencephalopathy) are adverse events of special interest (AESIs). Timely capture, reporting, and reconciliation are critical.
• Hypogammaglobulinaemia and immunoglobulin monitoring. Sustained B-cell depletion can lower serum immunoglobulins (IgG, IgM, IgA). Protocol-defined immunoglobulin monitoring and any dose-withholding/management rules must be executed and documented; missed or mishandled samples are a monitored risk.
• Injection reactions and immunogenicity. Injection-site and systemic injection reactions, and the potential for ADA formation affecting exposure or safety, require accurate event capture and correct ADA/PK sampling.
• Pharmacodynamic endpoint integrity. CD19+ B-cell flow-cytometry samples are time-sensitive and central to demonstrating mechanism; invalid, missing, or delayed samples degrade a critical dataset.
• Primary/secondary efficacy endpoint integrity. Accurate, consistently scored SLEDAI-2K, SRI-4 components, and adherence to the protocol corticosteroid taper are critical to interpretability.
• Blinding and randomization integrity. Correct IWRS use, concealment of allocation, and control of unblinding protect internal validity.
• Investigational product handling. Cold-chain maintenance, accountability, and correct subcutaneous administration are critical to exposure and safety.

Each factor is assigned a risk rating (likelihood, impact, detectability) in the IQRM; monitoring activities in Sections 6–16 are mapped to these ratings so that effort concentrates where the consequence of error is greatest.

5. Roles, Responsibilities, and Qualifications

Clinical Research Associate (CRA)/site monitor. Conducts qualification, initiation, interim, and close-out visits; performs source-data review and verification per this plan; verifies consent, eligibility, IP handling, safety reporting, and endpoint source; identifies and follows protocol deviations; and documents findings in monitoring visit reports with tracked resolution. Monitors are blinded to treatment assignment.

Central/centralised monitors and data analysts. Perform ongoing centralised review of EDC and external data, compute and trend KRIs and QTLs, detect anomalous patterns (e.g., outlier variability, digit preference, improbable timing), and trigger targeted site actions.

Clinical Trial Manager / Clinical Lead. Owns the monitoring strategy, oversees CRA activities and reporting, and adjudicates escalations and monitoring-intensity changes.

Medical Monitor. Provides medical oversight of safety and eligibility questions, supports causality and AESI assessment in coordination with the Safety Management Plan (TMF-006), and interfaces with the DSMB process (TMF-004). The Medical Monitor is functionally independent of the CRA line.

Qualifications and training. All monitors are qualified by education, training, and experience, and complete study-specific training on the protocol, this CMP, the SLE endpoint instruments, the modality-specific safety profile of a B-cell-depleting bispecific antibody, IP handling, EDC, and applicable procedures before independent monitoring. Training is documented and retained in the TMF.

6. Site Qualification Visits

Prior to site selection, a Site Qualification Visit (SQV) — conducted on-site or remotely as risk permits — confirms that the site has an appropriately qualified and available principal investigator and staff; an adequate and eligible subject population for moderate-to-severe active SLE; suitable facilities for refrigerated (2–8 °C) storage and controlled dispensing of a biologic, for subcutaneous administration, and for post-dose observation; capability and procedures for time-sensitive PD (flow-cytometry), PK, ADA, and safety-laboratory sample collection, processing, and shipment; adequate infection-screening and management capability given the B-cell-depletion risk profile; and the infrastructure, quality systems, and regulatory/ethics standing to conduct the study. Findings are documented, and site selection decisions are recorded in the TMF.

7. Site Initiation Visits

A Site Initiation Visit (SIV) is completed and documented before a site may screen or enrol subjects. The SIV confirms that all essential documents are in place, that IRB/IEC approval and the clinical trial agreement (TMF-013) are executed, and that IP and supplies have been received under controlled conditions. Site staff are trained on the protocol and amendments, informed consent process (TMF-001), eligibility and infection-screening requirements, IWRS/randomization (TMF-012), IP storage/preparation/subcutaneous administration and accountability (TMF-010), the laboratory and sample-handling procedures for PD/PK/ADA and safety labs (TMF-011), AE/SAE and AESI identification and reporting timelines (TMF-006), protocol-deviation handling, and EDC data entry (TMF-002). The delegation log, training records, and site-readiness confirmation are filed in the TMF, and the green-light to activate is formally recorded.

8. Routine On-Site (Interim) Monitoring Visits

Routine interim monitoring visits (IMVs) are scheduled on a risk-adjusted cadence — anchored to enrolment, subject exposure, and site performance rather than a fixed calendar — with an initial post-first-subject visit to confirm processes early, and increased frequency for sites showing risk signals. At each IMV the monitor verifies informed consent currency and adequacy; confirms continued eligibility and correct randomization; reviews IP receipt, storage-temperature records and excursion handling, accountability, and correct subcutaneous administration and dose; reviews safety data with particular attention to infections, hypogammaglobulinaemia, injection reactions, and other AESIs and their timely reporting; performs targeted source-data review and verification of critical variables (Section 10); confirms PD/PK/ADA and safety-lab samples were collected, handled, and shipped per the Laboratory Manual; reviews protocol deviations and corrective actions; assesses essential-document completeness in the investigator site file; and follows up open action items from prior visits. Visit scope may be adjusted for cause. A confirmation and, where required, a follow-up letter are issued, and a monitoring visit report is completed per Section 17.

9. Centralised Monitoring and Statistical Surveillance

Centralised monitoring runs continuously and in parallel with on-site activity, using accumulating EDC, laboratory, IP-temperature, and operational data to detect issues that site visits alone would miss. Analyses include site-to-site comparisons of key metrics; detection of anomalous data patterns (unexpectedly low variance, digit preference, implausible visit timing, duplicate or outlier values); trending of enrolment, query, deviation, and AE/SAE reporting rates; surveillance of missing or invalid critical samples (notably CD19+ B-cell flow cytometry and immunoglobulin panels); and monitoring of IP temperature-excursion frequency. Signals feed the KRI/QTL framework (Section 11) and can trigger remote follow-up, additional training, or for-cause on-site visits. Centralised monitoring also enables reduction of on-site source-data verification for consistently high-performing sites while preserving oversight of critical data.

10. Source Data Review and Source-Data Verification Strategy

Consistent with ICH E6(R3), OBX319-301 applies a risk-proportionate source-data review (SDR) and source-data verification (SDV) strategy rather than uniform 100% verification. SDR — the review of source for quality, consistency, protocol compliance, and safety plausibility — is applied broadly, while SDV — the direct comparison of eCRF entries against source — is concentrated on critical data.

Critical data verified at 100% include: informed consent (presence, version, dating, and process); key eligibility and safety-screening criteria (SLE disease-activity qualification and infection screening including TB, HBV, and HCV, and baseline immunoglobulins); investigational product administration records (dose, date, lot, and subcutaneous injection details); serious adverse events, deaths, and AESIs (serious/opportunistic infection, hypogammaglobulinaemia, injection reactions); the primary and key secondary endpoint source (SLEDAI-2K, SRI-4 components, physician global assessment, BILAG scoring) together with the protocol-mandated background corticosteroid taper that conditions the endpoint; and the critical PD, PK, and ADA sample collection records. Non-critical data are subject to reduced, sampling-based SDV and to centralised checks.

The proportion and focus of SDV are dynamic: they increase for cause at sites or on variables showing discrepancies, and may decrease where quality is demonstrated. The strategy, including the critical-data list and any changes to verification intensity, is documented and version-controlled.

11. Key Risk Indicators and Quality Tolerance Limits

Key Risk Indicators (KRIs) are pre-defined, quantitative site- and study-level metrics tracked over time to flag emerging risk, including: subject screen-failure and randomization-error rates; overdue or discrepant SAE reporting; eCRF entry lag and query volume/aging; protocol-deviation frequency; rates of missing or invalid critical samples (CD19+ B-cell flow cytometry, immunoglobulin, PK, ADA); IP temperature-excursion frequency; visit-window nonadherence; and subject discontinuation/withdrawal rates. KRI thresholds trigger graded responses from remote follow-up to for-cause on-site monitoring.

Quality Tolerance Limits (QTLs) are study-level parameters defining the range of acceptable variation for factors critical to subject safety and reliability of results; excursions prompt root-cause analysis and documented action. Illustrative QTLs for this study address: the rate of subjects with primary-endpoint-relevant data lost to follow-up; the rate of significant protocol deviations affecting the primary or key secondary endpoint (including deviations from the corticosteroid taper); the rate of missing or invalid critical PD (B-cell) samples; SAE/safety data-reconciliation discrepancy rates; and the rate of IP handling/administration errors. QTL definitions, thresholds, and any breaches and responses are documented and, where relevant to safety, coordinated with the DSMB (TMF-004) and Safety Management Plan (TMF-006).

12. Informed Consent Monitoring

At initiation and at every subsequent monitoring visit, the monitor verifies that valid informed consent was obtained before any study procedure; that the correct, IRB/IEC-approved version of the consent (TMF-001) was used and re-consent performed when required by amendments; that consent documents are properly dated and signed by the subject and the person conducting the consent discussion; and that the process afforded adequate time and opportunity for questions. Consent verification is a 100% activity across enrolled subjects. Any consent deficiency is documented as a deviation, escalated, and reported to the IRB/IEC and sponsor as required.

13. Safety Data Oversight and SAE Reconciliation

Monitoring reinforces the safety framework of the Safety Management Plan (TMF-006). Monitors verify that adverse events, serious adverse events, and AESIs are identified from source, accurately captured in the eCRF, assessed for seriousness, severity, and causality by the investigator, and reported within required timelines. Special attention is given to the identified class risks of B-cell depletion — serious and opportunistic infections, HBV reactivation, and hypogammaglobulinaemia — and to injection reactions and immunogenicity-related events. Monitors confirm that protocol-specified safety laboratory assessments (including immunoglobulins) and any consequent dose-withholding or management actions are performed and documented. Periodic SAE reconciliation between the clinical database and the safety/pharmacovigilance database is performed and documented to confirm completeness and consistency. Aggregate safety data flow to the DSMB per its charter (TMF-004).

14. Investigational Product Accountability and Cold-Chain Oversight

Because OBX-319 is a temperature-sensitive biologic requiring 2–8 °C storage, protection from light, and avoidance of freezing and agitation, IP oversight is a defined monitoring focus. Monitors verify receipt records; continuous temperature monitoring and the documentation and handling of any excursions (including quarantine and disposition decisions); secure, access-controlled storage; correct preparation and subcutaneous administration; unit-level accountability from receipt through administration to return/destruction; and reconciliation of dispensed, administered, and returned/destroyed units against IWRS records (TMF-012) and the Pharmacy Manual (TMF-010). Blinding of active and placebo supplies is confirmed to be maintained throughout handling.

15. Pharmacodynamic, Pharmacokinetic, and Immunogenicity Sample Oversight

The mechanism-defining and exposure-defining datasets for OBX-319 require rigorous sample oversight. Monitors confirm, against the Laboratory Manual (TMF-011) and protocol schedule, that: CD19+ B-cell enumeration samples are drawn at the correct visits and handled within the time and temperature constraints required for valid flow cytometry, then shipped to the central laboratory without avoidable delay; PK samples are collected at protocol-specified times, recognising that TMDD makes exposure sensitive to the B-cell target sink and thus to correct timing; ADA (and, where triggered, neutralising-antibody) samples are collected on schedule, since immunogenicity is a relevant determinant of exposure and safety; and supporting biomarkers (anti-dsDNA, complement C3/C4) are collected as specified. Missing, mistimed, or mishandled critical samples are tracked as KRIs and, above threshold, as QTL excursions, and are followed for root cause and corrective action.

16. Protocol Deviation Identification and Management

Monitors identify protocol deviations through source-data review, centralised analytics, and site interaction, and ensure each is documented, categorised by severity (with major/critical deviations — e.g., eligibility violations, consent failures, IP administration errors, endpoint-instrument or corticosteroid-taper deviations, and safety-reporting failures — clearly distinguished from minor), root-caused, and corrected. Deviation trends by site and by category feed the KRI/QTL framework and inform monitoring intensity, corrective and preventive action (CAPA), and, where required, reporting to the IRB/IEC and regulatory authorities. Recurrent or systemic deviations trigger escalation and, if warranted, for-cause monitoring.

17. Monitoring Visit Documentation and Follow-Up

Each monitoring contact is documented in a monitoring visit report that records the activities performed, data reviewed, findings and observations, actions required, responsible parties, and target resolution dates; open items are tracked to closure and reviewed at subsequent visits. Confirmation and follow-up letters are issued as applicable. Monitoring reports and related correspondence are reviewed by the responsible manager and filed in the TMF. Documentation is contemporaneous, attributable, legible, and complete, supporting reconstruction of the monitoring history and inspection readiness.

18. Close-Out Visits

A Site Close-Out Visit (COV) is conducted when a site completes participation or is closed for other reasons. The monitor confirms that all data are entered, queries resolved, and outstanding SDR/SDV completed; that all SAEs and AESIs are reported and reconciled; that IP is fully accounted for and returned or destroyed with documentation; that the investigator site file is complete and reconciled against the sponsor TMF; that essential-document retention, sample disposition, and any ongoing safety-follow-up obligations are addressed; and that the site is informed of record-retention requirements and of provisions for subject notification and continuing care as applicable. The COV is documented in a close-out report filed in the TMF.

19. Trial Master File and Records

Monitoring generates and relies on essential documents that are filed and maintained contemporaneously in the TMF to permit reconstruction and evaluation of trial conduct and data quality. Monitors periodically review investigator site files for completeness and consistency with the sponsor TMF, and confirm that access controls, versioning, and retention meet regulatory and sponsor requirements. Records are retained for the period required by applicable regulation.

20. Quality Assurance, Audit, and Inspection Readiness

Monitoring (a line-management quality-control function) is distinct from and complementary to independent quality assurance audit. This plan supports audit and regulatory-inspection readiness by ensuring critical data are verifiable to source, safety reporting is timely and reconciled, IP and blinding integrity are demonstrable, and deviations and CAPAs are documented. Audit findings and inspection outcomes that affect risk are fed back into the IQRM and may adjust monitoring intensity. Monitoring activities and their documentation are themselves subject to QA review.

21. Communication and Escalation

Routine monitoring communication flows between site staff, CRAs, central monitors, and the Clinical Trial Manager, with the Medical Monitor engaged for safety and eligibility questions. Defined escalation paths address urgent safety concerns, suspected fraud or serious noncompliance, blinding compromise, QTL breaches, and material data-integrity issues, ensuring timely notification of sponsor management and, where indicated, the DSMB (TMF-004), IRB/IEC, and regulatory authorities. Escalations and their resolutions are documented in the TMF.

22. References

• ICH E6(R3) — Good Clinical Practice.
• ICH E2A — Clinical Safety Data Management (via TMF-006, Safety Management Plan).
• ICH E9 — Statistical Principles for Clinical Trials (via TMF-004 and TMF-012).
• Study protocol OBX319-301 and amendments.
• TMF-001 Informed Consent Form; TMF-002 Data Management Plan; TMF-004 DSMB Charter; TMF-006 Safety Management Plan; TMF-010 Pharmacy Manual; TMF-011 Laboratory Manual; TMF-012 Randomization & IWRS Plan; TMF-013 Clinical Trial Agreement and IRB.